| 1 |
Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity [J]. Cell, 2020, 180(6): 1044-1066.
|
| 2 |
Gárate I, Garcia-Bueno B, Madrigal JL, et al. Stress-induced neuroinflammation: role of the Toll-like receptor-4 pathway [J]. Biol Psychiat, 2013, 73(1): 32-43.
|
| 3 |
Zhong J, Qiu X, Yu Q, et al. A novel polysaccharide from Acorus tatarinowii protects against LPS-induced neuroinflammation and neurotoxicity by inhibiting TLR4-mediated MyD88/NF-kappaB and PI3K/Akt signaling pathways [J]. Int J Biol Macromol, 2020, 163: 464-475.
|
| 4 |
Sharma S, Garg I, Ashraf MZ. TLR signalling and association of TLR polymorphism with cardiovascular diseases [J]. Vascul Pharmacol, 2016, 87: 30-37.
|
| 5 |
Lin CH, Chen HY, Wei KC. Role of HMGB1/TLR4 ax is in ischemia/re-perfusion-impaired extracellular glutamate clearance in primary astrocytes [J]. Cells, 2020, 9(12): 2585.
|
| 6 |
Leitner GR, Wenzel TJ, Marshall N, et al. Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders [J]. Expert Opin Ther Targets, 2019, 23(10): 865-882.
|
| 7 |
Jiang H, Wang Y, Liang X, et al. Toll-like receptor 4 knockdown attenuates brain damage and neuroinflammation after traumatic brain injury via inhibiting neuronal autophagy and astrocyte activation [J].Cell Mol Neurobiol, 2017, 38(5): 1009-1019.
|
| 8 |
Nalamolu KR, Smith NJ, Chelluboina B, et al. Prevention of the severity of post-ischemic inflammation and brain damage by simultaneous knockdown of toll-like receptors 2 and 4 [J]. Neuroscience, 2018, 373: 82-91.
|
| 9 |
Durán-Laforet V, Peña-Martínez C, García-Culebras A, et al. Pathophysiological and pharmacological relevance of TLR4 in peripheral immune cells after stroke [J]. Pharmacol Ther, 2021, 228: 107933.
|
| 10 |
Durán-Laforet V, Peña-Martínez C, García-Culebras A, et al. Role of TLR4 in neutrophil dynamics and functions: contribution to stroke pathophysiology [J]. Front Immunol, 2021, 12: 757872.
|
| 11 |
García-Culebras A, Durán-Laforet V, Peña-Martínez C, et al. Role of TLR4 (toll-like receptor 4) in N1/N2 neutrophil programming after stroke [J]. Stroke, 2019, 50(10): 2922-2932.
|
| 12 |
Morales I, Guzmán-Martínez L, Cerda-Troncoso C, et al. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches [J]. Front Cell Neurosci, 2014, 8: 112.
|
| 13 |
He Y, Ruganzu JB, Jin H, et al. LRP1 knockdown aggravates Aβ1-42-stimulated microglial and astrocytic neuroinflammatory responses by modulating TLR4/NF-κB/MAPKs signaling pathways [J]. Exp Cell Res, 2020, 394(2): 112166.
|
| 14 |
Guo MF, Zhang HY, Li YH, et al. Fasudil inhibits the activation of microglia and astrocytes of transgenic Alzheimer's disease mice via the downregulation of TLR4/Myd88/NF-κB pathway [J]. J Neuroimmunol, 2020, 346: 577284.
|
| 15 |
Vollmar P, Kullmann JS, Thilo B, et al. Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system [J]. J Immunol (Baltimore, Md: 1950), 2010, 185(10): 6338-6347.
|
| 16 |
Yeh FL, Hansen DV, Sheng M. TREM2, microglia, and neurodegenerative diseases [J]. Trends Mol Med, 2017, 23(6): 512-533.
|
| 17 |
Ruganzu JB, Peng X, He Y, et al. Downregulation of TREM2 expression exacerbates neuroinflammatory responses through TLR4-mediated MAPK signaling pathway in a transgenic mouse model of Alzheimer's disease [J]. Mol Immunol, 2022, 142: 22-36.
|
| 18 |
Caputi V, Giron MC. Microbiome-gut-brain axis and toll-like receptors in Parkinson's disease [J]. Int J Mol Sci, 2018, 19(6): 1689.
|
| 19 |
Kouli A, Horne CB, Williams-Gray CH. Toll-like receptors and their therapeutic potential in Parkinson's disease and α-synucleinopathies [J]. Brain Behav Immun, 2019, 81: 41-51.
|
| 20 |
Campolo M, Paterniti I, Siracusa R, et al. TLR4 absence reduces neuro-inflammation and inflammasome activation in Parkinson's diseases in vivo model [J]. Brain Behav Immun, 2019, 76: 236-247.
|
| 21 |
Qin Y, Liu Y, Hao W, et al. Stimulation of TLR4 attenuates Alzheimer's disease-related symptoms and pathology in tau-transgenic mice [J]. J Immunol, 2016, 197(8): 3281-3292.
|
| 22 |
Choi I, Zhang Y, Seegobin SP, et al. Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration [J]. Nat Commun, 2020, 11(1): 1386.
|
| 23 |
Perez-Pardo P, Dodiya HB, Engen PA, et al. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice [J]. Gut, 2019, 68(5): 829-843.
|
| 24 |
Okada T, Suzuki H. Toll-like receptor 4 as a possible therapeutic target for delayed brain injuries after aneurysmal subarachnoid hemorrhage [J]. Neural Regen Res, 2017, 12(2): 193-196.
|
| 25 |
Ma C, Zhou W, Yan Z, et al. Toll-like receptor 4 (TLR4) is associated with cerebral vasospasm and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage [J]. Neurol Med Chir (Tokyo), 2015, 55(12): 878-884.
|
| 26 |
Okada T, Kawakita F, Nishikawa H, et al. Selective toll-like receptor 4 antagonists prevent acute blood-brain barrier disruption after subarachnoid hemorrhage in mice [J]. Mol Neurobiol, 2019, 56(2): 976-985.
|
| 27 |
郝广志, 邹正, 陈立刚, 等. TLR4-NLRP3介导蛛网膜下腔出血早期大鼠神经细胞焦亡 [J]. 神经解剖学杂志, 2022, 38(1): 74-78.
|
| 28 |
El-Sisi AEE, Sokar SS, Shebl AM, et al. Octreotide and melatonin alleviate inflammasome-induced pyroptosis through inhibition of TLR4-NF-κB-NLRP3 pathway in hepatic ischemia/reperfusion injury [J]. Toxicol Appl Pharmacol, 2021, 410: 115340.
|
| 29 |
Ahmed H, Khan MA, Kahlert UD, et al. Role of adaptor protein myeloid differentiation 88 (myd88) in post-subarachnoid hemorrhage inflammation: a systematic review [J]. Int J Mol Sci, 2021, 22(8): 4185.
|
| 30 |
Asadzadeh Manjili F, Yousefi-Ahmadipour A, Kazemi Arababadi M. The roles played by TLR4 in the pathogenesis of multiple sclerosis; A systematic review article [J]. Immunol Lett, 2020, 220: 63-70.
|
| 31 |
Labib DA, Ashmawy I, Elmazny A, et al. Toll-like receptors 2 and 4 expression on peripheral blood lymphocytes and neutrophils of Egyptian multiple sclerosis patients [J]. Int J Neurosci, 2022, 132(4): 323-327.
|
| 32 |
Church JS, Milich LM, Lerch JK, et al. E6020, a synthetic TLR4 agonist, accelerates myelin debris clearance, Schwann cell infiltration, and remyelination in the rat spinal cord [J]. Glia, 2017, 65(6): 883-899.
|
| 33 |
Ding Y, Botchway BOA, Zhang Y, et al. The combination of autologous mesenchymal stem cell-derived exosomes and neurotrophic factors as an intervention for amyotrophic lateral sclerosis [J]. Ann Anat, 2022, 242: 151921.
|
| 34 |
Lee JD, Liu N, Levin SC, et al. Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis [J]. J Neuroinflammation, 2019, 16(1): 45.
|
| 35 |
Paudel YN, Angelopoulou E, Piperi C, et al. Implication of HMGB1 signaling pathways in Amyotrophic lateral sclerosis (ALS): From molecular mechanisms to pre-clinical results [J]. Pharmacol Res, 2020, 156: 104792.
|
| 36 |
Cui W, Sun C, Ma Y, et al. Inhibition of TLR4 induces M2 microglial polarization and provides neuroprotection via the NLRP3 inflammasome in Alzheimer's disease [J]. Front Neurosci, 2020, 14: 444.
|
| 37 |
Hua F, Tang H, Wang J, et al. TAK-242, an antagonist for Toll-like receptor 4, protects against acute cerebral ischemia/reperfusion injury in mice [J]. J Cereb Blood Flow Metab, 2015, 35(4): 536-542.
|
| 38 |
张娟, 尚德静. Toll样受体4(TLR4)信号通路及其靶向药物的研究进展 [J]. 细胞与分子免疫学杂志, 2021, 37(7): 657-662.
|
| 39 |
Kaushik D, Bhandari R, Kuhad A. TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2 [J]. Expert Opin Ther Targets, 2021, 25(6): 491-508.
|
| 40 |
Ye T, Li Y, Xiong D, et al. Combination of Danshen and ligustrazine has dual anti-inflammatory effect on macrophages and endothelial cells [J]. J Eth-nopharmacol, 2021, 266: 113425.
|
| 41 |
Kouli A, Horne CB, Williams-Gray CH. Toll-like receptors and their therapeutic potential in Parkinson's disease and α-synucleinopathies [J]. Brain Behav Immun, 2019, 81: 41-51.
|
| 42 |
Azam S, Jakaria M, Kim IS, et al. Regulation of toll-like receptor (TLR) signaling pathway by polyphenols in the treatment of age-linked neurodegenerative diseases: focus on TLR4 signaling [J]. Front Immunol, 2019, 10: 1000.
|
| 43 |
Le K, Song Z, Deng J, et al. Quercetin alleviates neonatal hypoxic-ischemic brain injury by inhibiting microglia-derived oxidative stress and TLR4-mediated inflammation [J]. Inflamm Res, 2020, 69(12): 1201-1213.
|
| 44 |
Li R, Zhou Y, Zhang S, et al. The natural (poly)phenols as modulators of microglia polarization via TLR4/NF-κB pathway exert anti-inflammatory activity in ischemic stroke [J]. Eur J Pharmacol, 2022, 914: 174660.
|
| 45 |
Song W, Wang T, Shi B, et al. Neuroprotective effects of microRNA-140-5p on ischemic stroke in mice via regulation of the TLR4/NF-κB axis [J]. Brain Res Bull, 2021, 168: 8-16.
|
| 46 |
Yan Y, Xia H, Hu J, et al. MicroRNA-542-3p regulates p-glycoprotein ex-pression in rat epilepsy via the toll-like receptor 4/nuclear factor-kappa B signaling pathway [J]. Curr Neurovasc Res, 2019, 16(5): 433-440.
|
| 47 |
Zhou Q, Wang Q, He B, et al. MicroRNA-322-5p reduced neuronal infla-mmation via the TLR4/TRAF6/NF-κB axis in a rat epilepsy model [J]. Open Med (Wars), 2022, 17(1): 907-914.
|